The price of one of the most commonly prescribed treatments for Parkinson’s disease has surged more than 200 percent over the past decade. That’s making the drug, Teva Pharmaceutical’s Azilect, ...

Patient Share of Teva/Lundbeck’s Azilect among Recently Treated Parkinson’s Disease Patients Grew 8 Percent Year over Year Decision Resources, one of the world’s leading research and advisory firms ...

JERUSALEM & VALBY, Denmark--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect ® (rasagiline ...

Surveyed Neurologists and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine Agonists, According to a New Report from Decision Resources WALTHAM, Mass., March 4 /PRNewswire/ -- ...

Teva Pharmaceutical Industries and Lundbeck have presented new data from a late-stage trial of Azilect which suggest that the already-marketed drug could become the first disease-modifying treatment ...

Jersulam, Israel, December 14, 2009 - Teva Pharmaceutical Industries, Ltd. (NASDAQ:TEVA) today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information ...

DUBLIN--(BUSINESS WIRE)--The "Azilect" report has been added to Research and Markets' offering. Azilect (Teva) is a pure isomer of rasagiline and is the most recent selective irreversible monoamine ...

JERUSALEM — Teva on Monday announced that the Food and Drug Administration approved an expanded label for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include dopamine ...

Teva Pharmaceuticals announced that the FDA has approved revised Prescribing Information for Azilect (rasagiline tablets) reducing medication and food restrictions. The new labeling reflects reduced ...

September 11, 2006 — Health Canada has approved rasagiline 0.5- and 1-mg tablets for use as initial monotherapy in the treatment of early Parkinson's disease and as an adjunct to levodopa therapy for ...

TEL AVIV/STOCKHOLM, June 16 (Reuters) - Teva Pharmaceutical Industries Ltd reported positive results on Monday for its Azilect Parkinson's treatment, boosting its shares and those of Danish partner ...